|Videos|November 14, 2022
Identifying HABP/VABP Priorities
Author(s)John Parkinson
An ICU hospitalist talks about his criteria and the treatment protocols for these cases.
Advertisement
Hospital-acquired bacterial pneumonia (HABP) and ventilator-acquired bacterial pneumonia (VABP) continue to remain challenging infections for clinicians to treat.
For those patients diagnosed with VABP, their conditions can prolong their hospital stays. And for those patients in the ICU, VABP patients can mean not only longer hospitalization, but wider antibiotic coverage, more respiratory therapy, and more tests such as x-rays and labs.
For those patients diagnosed with HABP, they may not be considered as severe as VABP, but there is a high rate of complications. For both subsets of patients, HABP/VABP can also see multidrug resistance.
Overall, there are several prevalent pathogens of HABP/VABP including: S aureus, P aeruginosa, Klebsiella species, E coli, Acinetobacter species, and Enterobacter species, which consistently cause up to 80% of all HABP or VABP episodes.
Christian Sandrock, MD, MPH, FCCP and his staff at UC Davis Medical Center are looking at risk profiles and considering existing treatment guidelines when they are seeing these patients.
Sandrock who is vice chair for Quality and Safety; division vice chief of Internal Medicine; director of Critical Care; and professor of Medicine at UC Davis sat down with Contagion as part of an ongoing short series of video interviews to discuss these pathogens and infections. In the far-ranging interview, Sandrock discusses how his institution is handling treatment, protocols on HABP/VABP, and his perspective on the therapy pipeline.
In this episode, Sandrock discusses criteria and risk factors for antimicrobial treatment for HABP/VABP.
Advertisement
Related to this article
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4,080 confirmed cases, 78% above all of 2025.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.